Noemí Gómez-Lado

Noemí Gómez-Lado

Auto-generated profile, based on publicly available information

Noemí Gómez-Lado

Molecular Imaging and Pharmacokinetic Modelling Group, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
NGNoemí Gómez-Lado
Noemí Gómez-Lado
ISIria Seoane-Viaño
Iria Seoane-Viaño
SMSilvia Matiz
Silvia Matiz
CMChristine Madla
Christine Madla
VYVipul Yadav
Vipul Yadav
AGAlvaro Goyanes
Alvaro Goyanes
Following oral administration, gastric emptying is often a rate-limiting step in the absorption of drugs and is dependent on both physiological and pharmaceutical factors. To guide translation into humans, small animal imaging during pre-clinical studies has been increasingly used to localise the gastrointestinal transit of solid dosage forms. In contrast to humans, however, anaesthesia is usually required for effective imaging in animals which may have unintended effects on intestinal physiology. This study evaluated the effect of anaesthesia and capsule size on the gastric emptying rate of coated capsules in rats. Computed tomography (CT) imaging was used to track and locate the capsules through the gastrointestinal tract. Two commercial gelatine mini-capsules (size 9 and 9h) were filled with barium sulphate (contrast agent) and coated using Eudragit L. Under the effect of anaesthesia, none of the capsules emptied from the stomach. In non-anaesthetised rats, most of the size 9 capsules did not empty from the stomach, whereas the majority of the smaller size 9h capsules successfully emptied from the stomach and moved into the intestine. This study demonstrates that even with capsules designed to empty from the stomach in rats, the gastric emptying of such solid oral dosage forms is not guaranteed. In addition, the use of anaesthesia was found to abolish gastric emptying of both capsule sizes. The work herein further highlights the utility of CT imaging for the effective visualisation and location of solid dosage forms in the intestinal tract of rats without the use of anaesthesia.

1 August 2021 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
SDSandra Díez-Villares
Sandra Díez-Villares
Juan PellicoJuan Pellico
Juan Pellico
NGNoemí Gómez-Lado
Noemí Gómez-Lado
SGSantiago Grijalvo
Santiago Grijalvo
SASandra Alijas
Sandra Alijas
MFMaria De la Fuente
Maria De la Fuente
Background and Purpose: Non-invasive imaging methodologies, especially nuclear imaging techniques, have undergone an extraordinary development over the last years. Interest in the development of innovative tracers has prompted the emergence of new nanomaterials with a focus on nuclear imaging and therapeutical applications. Among others, organic nanoparticles are of the highest interest due to their translational potential related to their biocompatibility and biodegradability. Our group has developed a promising new type of biocompatible nanomaterials, sphingomyelin nanoemulsions (SNs). The aim of this study is to explore the potential of SNs for nuclear imaging applications. Methods: Ready-to-label SNs were prepared by a one-step method using lipid derivative chelators and characterized in terms of their physicochemical properties. Stability was assessed under storage and after incubation with human serum. Chelator-functionalized SNs were radiolabeled with 67Ga and 68Ga, and the radiochemical yield (RCY), radiochemical purity (RCP) and radiochemical stability (RCS) were determined. Finally, the biodistribution of 67/68Ga-SNs was evaluated in vivo and ex vivo. Results: Here, we describe a simple and mild one-step method for fast and efficient radiolabeling of SNs with 68Ga and 67Ga radioisotopes. In vivo experiments showed that 67/68Ga-SNs can efficiently and indistinctly be followed up by PET and SPECT. Additionally, we proved that the biodistribution of the 67/68Ga-SNs can be conveniently modulated by modifying the surface properties of different hydrophilic polymers, and therefore the formulation can be further adapted to the specific requirements of different biomedical applications. Conclusion: This work supports 67/68Ga-SNs as a novel probe for nuclear imaging with tunable biodistribution and with great potential for the future development of nanotheranostics.

26 July 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
ACAndrea Cuartero-Martínez
Andrea Cuartero-Martínez
Xurxo García-OteroXurxo García-Otero
Xurxo García-Otero
JCJessica Codesido
Jessica Codesido
NGNoemí Gómez-Lado
Noemí Gómez-Lado
JMJesús Mateos Martín
Jesús Mateos Martín
Anxo Fernández-FerreiroAnxo Fernández-Ferreiro
Anxo Fernández-Ferreiro
Uveitis is a group of inflammatory ocular pathologies. Endotoxin-Induced Uveitis (EIU) model represent a well-known model induced by administration of Lipopolysaccharide (LPS). The aim is to characterize two models of EIU through two routes of administration with novel noninvasive imaging techniques. 29 rats underwent Intraocular Pressure (IOP) measurements, Optical Coherence Tomography (OCT), proteomic analysis, and Positron Emission Tomography and Computed Tomography (PET/CT). Groups included healthy controls (C), BSS administered controls (Ci), systemically induced EIU with LPS (LPSs), and intravitreally induced EIU with LPS (LPSi) for IOP, OCT, and proteomic studies. For 18F-FDG PET/CT study, animals were divided into FDG-C, FDG-LPSs and FDG-LPSi groups and scanned using a preclinical PET/CT system. LPSi animals exhibited higher IOP post-induction compared to C and LPSs groups. LPSi showed increased cellular infiltrate, fibrotic membranes, and iris inflammation. Proinflammatory proteins were more expressed in EIU models, especially LPSi. PET/CT indicated higher eye uptake in induced models compared to FDG-C. FDG-LPSi showed higher eye uptake than FDG-LPSs but systemic uptake was higher in FDG-LPSs due to generalized inflammation. OCT is valuable for anterior segment assessment in experimental models. 18F-FDG PET/CT shows promise as a noninvasive biomarker for ocular inflammatory diseases. Intravitreal induction leads to higher ocular inflammation. These findings offer insights for future inflammatory disease research and drug studies.

5 June 2025 in Drug Delivery and Translational Research
Verified
Journal Article
Open access
PDF file
RVRubén Varela-Fernández
Rubén Varela-Fernández
Xurxo García-OteroXurxo García-Otero
Xurxo García-Otero
ACAndrea Cuartero-Martínez
Andrea Cuartero-Martínez
NGNoemí Gómez-Lado
Noemí Gómez-Lado
MGMiguel González-Barcia
Miguel González-Barcia
Francisco Otero-EspinarFrancisco Otero-Espinar
Francisco Otero-Espinar
Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF) for treating neovascular and oncological conditions, faces challenges in biodistribution and targeted delivery. Nanoparticle-based drug delivery systems have shown promise in enhancing the pharmacokinetic profiles of biologic drugs. This study aimed to develop and characterize bevacizumab-loaded PLGA nanoparticles to modify antibody’s distribution and improve its therapeutic efficacy. Characterization studies, morphological examination, release profile determination, stability and physical properties were conducted. Biodistribution was studied in rats using PET/CT imaging. Optimized nanoparticles were spherical (around 300 nm) and surface charge (about − 20 mV). Encapsulation efficiency and drug loading varied from 75 to 95%. Stability studies demonstrated minimal changes in size and drug content over the studied period. In vitro release exhibited a biphasic pattern, with an initial burst followed by a sustained release phase. In vivo pharmacokinetics and distribution revealed altered antibody distribution by encapsulation into nanoparticles. Safety studies indicated no significant cytotoxicity or adverse effects. The developed bevacizumab nanoparticles demonstrated favorable physicochemical characteristics, stability, and release profiles. These findings warrant further investigation in disease-specific models to elucidate the clinical potential of this nanoparticle-based delivery system for bevacizumab, particularly in enhancing anti-angiogenic effects and overcoming barriers to effective delivery in target tissues. Graphical abstract

13 January 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
LGLara García-Varela
Lara García-Varela
JCJessica Codesido
Jessica Codesido
APAlberto Perez-Pedrosa
Alberto Perez-Pedrosa
MMMaría Muñoz-González
María Muñoz-González
EREmma Ramos-Docampo
Emma Ramos-Docampo
PAPablo Aguiar
Pablo Aguiar

26 September 2024 in NeuroImage
Verified
Journal Article
Open access
DRDavid Rey-Bretal
David Rey-Bretal
LGLara García-Varela
Lara García-Varela
NGNoemí Gómez-Lado
Noemí Gómez-Lado
AMAlexis Moscoso
Alexis Moscoso
MPManuel Piñeiro-Fiel
Manuel Piñeiro-Fiel
PAPablo Aguiar
Pablo Aguiar
SUV measurements from static brain [18F]FDG PET acquisitions are a commonly used tool in preclinical research, providing a simple alternative for kinetic modelling, which requires complex and time-consuming dynamic acquisitions. However, SUV can be severely affected by the animal handling and preconditioning protocols, primarily by those that may induce changes in blood glucose levels (BGL). Here, we aimed at developing and investigating the feasibility of SUV-based approaches for a wide range of BGL far beyond normal values, and consequently, to develop and validate a new model to generate standardized and reproducible SUV measurements for any BGL. We performed dynamic and static brain [18F]FDG PET acquisitions in 52 male Sprague-Dawley rats sorted into control (n=10), non-fasting (n=14), insulin-induced hypoglycemia (n=12) and glucagon-induced hyperglycemia (n=16) groups. Brain [18F]FDG PET images were cropped, aligned and co-registered to a standard template to calculate whole-brain and regional SUV. Cerebral Metabolic Rate of Glucose (CMRglc) was also estimated from 2-Tissue Compartment Model (2TCM) and Patlak plot for validation purposes. Our results showed that BGL=100±6 mg/dL can be considered a reproducible reference value for normoglycemia. Furthermore, we successfully established a 2nd-degree polynomial model (C1=0.66E-4, C2=-0.0408 and C3=7.298) relying exclusively on BGL measures at pre-[18F]FDG injection time, that characterizes more precisely the relationship between SUV and BGL for a wide range of BGL values (from 10 to 338 mg/dL). We confirmed the ability of this model to generate corrected SUV estimations that are highly correlated to CMRglc estimations (R2= 0.54 2TCM CMRgluc and R2= 0.49 Patlak CMRgluc). Besides, slight regional differences in SUV were found in animals from extreme BGL groups, showing that [18F]FDG uptake is mostly directed toward central regions of the brain when BGLs are significantly decreased. Our study successfully established a non-linear model that relies exclusively on pre-scan BGL measurements to characterize the relationship between [18F]FDG SUV and BGL. The extensive validation confirmed its ability to generate SUV-based surrogates of CMRglu along a wide range of BGL and it holds the potential to be adopted as a standard protocol by the preclinical neuroimaging community using brain [18F]FDG PET imaging.